Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249887 | 1.00 | HRH3 (0.56) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8394609 | 1.00 | HRH3 (0.56) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8392658 | 1.00 | HRH3 (0.56) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8393806 | 1.00 | HRH3 (0.56) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8392241 | 0.98 | HRH3 (0.54) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8397103 | 0.96 | HRH3 (0.53) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL3791428 | 0.96 | KDM4E (0.54) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8392252 | 0.94 | TPSAB1 (0.54) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8391191 | 0.94 | TPSAB1 (0.54) | HRH3KDM4EEPHX1HTTCA12 | |
| SCHEMBL8396874 | 0.92 | TPSAB1 (0.55) | HRH3KDM4EEPHX1HTTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104666299-A | 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof | GALDERMA RES & DEV | 2015-06-03 | — | — | CN | claimed |
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| CN-104666299-A | 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof | GALDERMA RES & DEV | 2015-06-03 | — | — | CN | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | HRH3 85/4885KDM4E 3975/4885EPHX1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.